Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
Castle Biosciences announced that its TissueCypher Barrett's Esophagus Test has surpassed 100,000 clinical test orders, marking a significant milestone in commercial adoption. The AI-derived precision medicine test predicts a patient's five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma.
Key figures
- Total orders
- 100000
- Patients studied
- 8000
- Peer reviewed publications
- 17
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.